David Barton, founder and owner of DavidBartonGym, has proclaimed for a second consecutive year that Sept. 24, 2011, be “Diane’s Day” in honor of Barton’s sister, Diane Barton. Last year’s campaign raised over $115,000 to improve treatment options for women with ovarian cancer.
All DavidBartonGym locations in New York, Chicago, Miami and Seattle will donate proceeds from every personal training session on “Diane’s Day” to The Clearity Foundation.
To raise additional awareness and funds, DavidBartonGym will host various local events, including a philanthropic luncheon at Vinter Grill The Strip at Neiman Marcus in Las Vegas, as well as a fashion presentation, styled by Barton. Additionally, GILT Group’s “Gilt Gives” will sell special training packages in local markets including New York, Chicago, Miami and Seattle, with all proceeds donated to the Clearity Foundation.
The Clearity Foundation optimized DavidBartonGym’s financial contribution in 2010 by creating the Diane Barton Database, a valuable and accessible platform to help women make better treatment decisions. By comparing each woman’s individual molecular profiling data against the Diane Barton Database, treatment choices can be personalized and prioritized.
“Ovarian cancer is hard to detect but harder to treat. I have partnered with an organization whose research benefits people right now and who need additional funding to continue to make improvements in treatment and detection. Every penny gets us one step closer to improving someone’s chances. I can’t emphasize enough the importance of acting now,” said David Barton, the founder of DavidBartonGym.
“Thanks to the money raised by DavidBartonGym, The Clearity Foundation has improved its database of tumor ‘blueprints’ and named it the Diane Barton Database, in honor of David’s sister, a physician who was only 45 years old when she passed away,” said Laura Shawver, Ph.D., the founder of The Clearity Foundation. “David is deeply committed to providing women with ovarian cancer resources that can positively impact their lives today. At The Clearity Foundation we offer resources to do just that.”
Ovarian cancer tumors vary from patient to patient and do not uniformly respond to FDA-approved treatment; therefore they need customized treatment plans. Molecular profiling enables the individualization of a patient’s treatment by matching tumor alterations with one or more drugs.
